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CDX1 and CDX2 Expression in Intestinal Metaplasia, Dysplasia 
and Gastric Cancer
Intestinal metaplasia (IM) has been regarded as a premalignant condition. However, the 
pathogenesis of IM is not fully understood. The aim of this study was to evaluate the role 
of CDX1 and CDX2 in the formation of IM and the progression to dysplasia and gastric 
cancer (GC). A total of 270 subjects included 90 with GC, dysplasia and age- and sex-
matched controls. Real-time PCR (RT-PCR) was performed with body specimens for CDX1 
and CDX2. The expression of CDX2 was significantly higher in H. pylori positive group than 
H. pylori negative group (P = 0.045). CDX1 and CDX2 expression increased proportional to 
the IM grade of the body (P < 0.001). CDX2 expression was significantly higher in 
incomplete type of IM than in complete type (P = 0.045). The expression of CDX1 in 
dysplasia group was significantly higher than in the control group (P = 0.001); in addition, 
CDX1 and CDX2 in cancer group was significantly higher than control group (P < 0.001, 
and P < 0.001, respectively). Aberrant expression of CDX1 and CDX2 correlated with H. 
pylori infection and grade of IM in the body. Furthermore, the results suggest that CDX1 
and CDX2 play a role in the progression to GC and dysplasia.
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INTRODUCTION
Gastric cancer (GC) is one of the most common malignancies 
in Korea. Correa (1) has suggested that intestinal GC develops 
through a sequence of histological changes, including diffuse 
chronic gastritis, mucosal atrophy, intestinal metaplasia (IM), 
dysplasia, and finally invasive carcinoma. Infection with Helico-
bacter pylori typically produces a chronic inflammatory condi-
tion that gives rise to IM. Gastric IM has been classified as com-
plete (small intestine) or incomplete (colon) using immunohis-
tochemical staining techniques. Another classification catego-
rizes IM into three types: I (complete), II and III (incomplete) (2). 
For type I, the morphology is similar to the small intestinal mu-
cosa where goblet cells secrete sialomucins, and Paneth cells are 
observed. For types II and III columnar cells are present where 
goblet cells secrete sulfomucins, but Paneth cells are not present. 
Type II IM typically exhibits the most extensive genetic chang-
es. Many prior studies have evaluated the significance of type 
III IM as a risk factor for the development of the intestinal-type 
of GC (3, 4). However, the development of IM in relationship to 
GC remains unclear. 
  CDX1 and CDX2 are members of the caudal-related homeo-
box gene family and are intestine-specific transcriptional fac-
tors (5, 6). In adult mice and humans, expression of CDX1 and 
CDX2 is strictly confined to the gut, from the duodenum to the 
rectum. While normal gastric mucosa does not express the tran-
scriptional factors CDX1 and CDX2, aberrant expression of CDX1 
and CDX2 is observed in animal and human gastric IM (7-10). 
These findings suggest that CDX1 and CDX2 may play a pivotal 
role in the development of IM in the human stomach. With re-
gard to GC, CDX2 is expressed in adenocarcinomas from vari-
ous organs such as the stomach, colon, pancreas, gallbladder 
and lungs, and may be clinically useful for improved prediction 
of the outcome of patients with advanced cancer (11, 12). In ad-Kang JM, et al.  •  CDX in Intestinal Metaplasia, Dysplasia, and Gastric Cancer
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dition, expression of CDX2 showed a significant positive corre-
lation with dysplasia and cancer (13). By contrast, several stud-
ies from surgical specimens reported a reduction of CDX1 and 
CDX2 in the GC compared to IM (7, 9, 14). Therefore, the role of 
CDX1 and CDX2 in GC remains unclear. Furthermore, no study 
has investigated the expression of both CDX1 and CDX2 on a 
background mucosa of dysplasia and cancer in human gastric epi-
thelium with respect to H. pylori infection, a main cause of IM. 
  Therefore both CDX1 and CDX2 expression in control subjects 
with dysplasia and patients with GC were studied. Furthermore, 
the relationship between the expression of these two proteins 
and the IM grade and subtype associated with H. pylori infec-
tion was investigated. 
MATERIALS AND METHODS
Study population
This study was performed at Seoul National University Bundang 
Hospital as a case-control study. Ninety patients with gastric can-
cer and 90 patients with dysplasia were enrolled from Septem-
ber 2003 to March 2007. Dysplasia includes low- and high-grade 
adenoma. Pathological diagnosis beyond adenocarcinoma in 
situ was classified into cancer group. Age- and sex-matched con-
trols that underwent endoscopy for health screening or evalua-
tion of upper gastrointestinal symptoms were eligible for par-
ticipation. Subjects with a history of gastric surgery, H. pylori 
eradication therapy, medication of antisecretory drugs or non-
steroidal anti-inflammatory drugs (NSAIDs), or systemic dis-
eases requiring chronic medication were excluded. Smoking 
was defined as “current” when consumption was more than 5 
cigarettes per day. 
H. pylori testing 
To determine the presence of current H. pylori infection, three 
types of H. pylori testing (histology, Campylobacter like organ-
ism [CLO] test [Delta West, Bentley, Australia] and culture) were 
used. One specimen from each of the lesser curvature of the an-
trum and the body was used for rapid urease testing (CLO test). 
Two specimens from the antrum and body were used for culture. 
The antral and body biopsy specimens were evaluated separate-
ly, and organisms were identified as H. pylori by Gram staining, 
colony morphology, and positive oxidase, catalase and urease 
reactions. If any one of these three H. pylori tests were positive 
then the host was regarded as having an ongoing H. pylori infec-
tion. The anti-H. pylori immunoglobulin G was also determined 
qualitatively using an enzyme-linked immunosorbent assay 
(Genedia H. pylori ELISA; Green Cross Medical Science Corp, 
Eumseong, Korea), especially when the three above-mentioned 
H. pylori tests were negative. When the H. pylori serology was pos-
itive but no bacteria were found on histology, CLO test or culture, 
these subjects were regarded as having past H. pylori infection 
without an ongoing infection, and classified as H. pylori-positive. 
IM grading and subtyping
Two specimens (one from the greater curvature and one from 
the lesser curvature) were obtained from the antrum and body, 
respectively, and assessed for the degree of IM (all determined 
by hematoxylin-eosin staining). The histological features of the 
gastric mucosa were recorded using the updated Sydney scor-
ing system (i.e., 0, none; 1, slight; 2, moderate; and 3, marked). 
The average of the score in the greater curvature and the lesser 
curvature were used for comparison between the groups. All 
biopsies were examined independently by two experienced pa-
thologists, who were unaware of the patient details. In the event 
of disagreement, the biopsies were reexamined by these two 
pathologists until agreement was reached.
  Samples were also stained with alcian blue (AB) and high iron 
diamine (HID) to categorize IM as the complete (Type I) or in-
complete (Type II and II). Slides were immersed in HID solu-
tion for 20 hr at room temperature, then rinsed with deionized 
water and stained with 1% AB for 2 min. IM subtyping was per-
formed according to the system reported by Filipe et al. (2) and 
Shiotani et al. (15). If more than one HID subtype of IM was pres-
ent, the dominant IM phenotype was used for classification. In 
addition, the pathologists were blinded to the clinical informa-
tion of the patients.
Real-time PCR of CDX1 and CDX2
Total RNA was extracted from body specimens (one from the 
greater curvature and one from the lesser curvature) of the gas-
tric mucosa using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). 
RNA samples were diluted to a final concentration of 0.5 mg/mL 
in RNase-free water and stored at -80°C until use. Synthesis of 
the cDNA was performed with 1 mg of total RNA with M-MLV 
reverse transcription reagents (Invitrogen), and real-time PCR 
reaction was carried out on the ABI PRISM 7000 Sequence De-
tection System (Applied Biosystems, Foster City, CA, USA) in 20 
μL TaqMan Gene Expression Master Mix (Applied Biosystems) 
using 200 ng cDNA. Target genes for CDX1 and CDX2 were test-
ed using Assay-on-Demand Gene Expression products. The pre-
designed primer sets were ordered according to http://www.
appliedbiosystems.com/ (CDX1 assay ID number: Hs00156451_
m1; CDX2 assay ID number: Hs01078080_m1; β-actin assay ID 
number: Hs99999903_m1) and used according to their proto-
cols. The reaction conditions were 50°C for 2 min and 95°C for 
10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
The human beta-actin gene was used as an endogenous refer-
ence to control for the independent expression of sample-to-
sample variability. The relative expression of target genes was 
normalized by dividing the target Ct values by the endogenous 
Ct values. All equipment was purchased from Applied Biosys-
tems and used according to their protocols. Kang JM, et al.  •  CDX in Intestinal Metaplasia, Dysplasia, and Gastric Cancer
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Statistical analysis
All statistical analyses were performed using SPSS software ver. 
15.0 (SPSS Software, Chicago, IL, USA). The Student’s t-test or 
the Pearson chi-square test were used to compare two groups. 
Correlations between IM grade and CDX1 and CDX2 expres-
sions were performed using the Pearson correlation test and 
partial correlation coefficients adjusted for disease group.
Ethics statement
The institutional review board of the Seoul National University 
Bundang Hospital approved this study (B-1009/111-006). Writ-
ten informed consent was obtained from all of the participants. 
RESULTS 
Baseline characteristics
A total of 270 patients in the study group included 90 with GC 
and 90 age- and sex-matched controls in addition to 90 patients 
with dysplasia. The gastric dysplasia biopsies were diagnosed as 
60 low-grade and 30 high-grade dysplasia. The baseline charac-
teristics are shown in Table 1. The H. pylori positivity and pro-
portion of current smoker in patients with cancer and dysplasia 
did not differ from the control group. The grade of IM in the an-
trum was significantly higher in the dysplasia group compared 
to the control group (P = 0.016). The grade of IM in the body was 
significantly higher in the dysplasia and cancer group compared 
to the control group (P < 0.001 and P < 0.001, respectively) (Table 
1). However, the subtype of IM was not different among the three 
different study groups. 
Relationships between CDX1/CDX2 expression and grade 
of IM
The expression of CDX1 and CDX2 in the body specimens were 
positively correlated with the grade of IM not only before (r = 
0.414, P < 0.001 and r = 0.380, P < 0.001, respectively) and but 
also after adjustment for 3 disease groups (partial r = 0.377, P < 
0.001 and partial r = 0.346, P < 0.001, respectively) (Fig. 1B, D). 
However, there was no significant correlation between the ex-
pression of CDX1/CDX2 and the grade of IM in the antrum not 
only before (r = 0.106, P = 0.081 and r = 0.067, P < 0.273, respec-
tively) but also after adjustment for 3 disease groups (partial r = 
0.091, P = 0.136 and partial r = 0.052, P = 0.392, respectively) (Fig. 
1A, C).
Comparisons of CDX1 and CDX2 expression in the control, 
dysplasia and cancer groups
The expression of CDX1 but not CDX2 in the dysplasia group was 
significantly higher than control group (P < 0.001, Fig. 2). When 
it comes to cancer group, the expression of CDX1 and CDX2 was 
significantly higher than the control group (P < 0.001 and P < 
0.001, respectively, Fig. 2). However, the expression of CDX1 and 
CDX2 between dysplasia group and cancer was not different. 
CDX1 and CDX2 expression by Real-time PCR according 
to H. pylori positivity, presence and subtype of IM
A comparison of the expression of CDX1 and CDX2 with respect 
to the presence of H. pylori and IM is shown in Table 2. With re-
gard to H. pylori positivity, the expression of CDX2 but not CDX1 
was significantly higher in the H. pylori positive group than the 
H. pylori negative group (P = 0.045). The expression of CDX1 and 
CDX2 was higher with IM than without IM in the body (P < 0.001 
and P < 0.001, respectively). Furthermore, expression of CDX2 
but not CDX1 was higher in the incomplete type of IM in the 
body (0.64 ± 0.04) compared to the complete type (0.46 ± 0.08) 
(P = 0.045) (Table 2). However, the expression of CDX1 and CDX2 
was not different with respect to the presence or the subtype of 
IM in the antrum.
DISCUSSION
In IM of the human stomach, normal gastric mucosa is replaced 
by an intestinalized epithelium; the progression of H. pylori-in-
fected chronic gastritis facilitates the development of IM. IM of 
the human stomach has been extensively studied as a prema-
lignant condition of gastric carcinoma (16). However, the forma-
tion and progression of IM is not completely understood; there 
Table 1. A comparison of baseline characteristics among control, dysplasia and gastric cancer groups 
Parameters Control (n = 90) Dysplasia (n = 90) Cancer (n = 90) P values* P values
†
Age (yr, mean ± SD) 63 ± 9 63 ± 9 63 ± 9 1.000 1.000
Male/Female 65/25 65/25 65/25 1.000 1.000
Current smokers (%) 20 (22.2) 17 (18.9) 26 (28.9) 0.580 0.305
H. pylori positivity (%) 72 (80.0) 79 (87.8) 74 (82.2) 0.156 0.703
Grade of IM (mean ± SD)
   Antrum
   Body
 
  1.37 ± 0.86
  0.73 ± 0.96
 
  1.70 ± 0.98
  1.29 ± 0.97
 
  1.52 ± 0.84
  1.29 ± 1.00
 
0.016
< 0.001
 
0.472
0.001
Subtype of IM (Complete/Incomplete)
   Antrum
   Body
 
  9/48
  8/26
 
  5/52
17/32
 
  7/47
  9/41
 
0.254
0.276
 
0.672
0.536
*P values indicate the difference between control vs dysplasia; 
†P values indicate the difference between control vs cancer. Bold letters mean statistical significance. SD, stan­
dard deviation. Kang JM, et al.  •  CDX in Intestinal Metaplasia, Dysplasia, and Gastric Cancer
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is limited information on the biology of IM in the medical liter-
ature (10, 17). Furthermore, the role of IM in the progression to 
GC is unclear. 
  The intestine-specific homeobox genes CDX1 and CDX2 have 
been shown to be aberrantly expressed in human IM (9, 10, 18). 
In the present study, CDX1 and CDX2 expression was strongly 
correlated with the grade of IM in the body, consistent with pre-
vious studies (14, 18, 19). However, there was no significant cor-
relation between the expression of CDX1/CDX2 and the grade 
of IM in the antrum. In addition, there was no significant differ-
ence in the expression of CDX1 and CDX2 according to the pres-
ence of IM in the antrum. This might be originated from the fact 
that RT-PCR for CDX1 and CDX2 was only performed using 
specimens from the body but not from antrum in the present 
Fig. 2. The comparison of the CDX1 and CDX2 expression according to disease group. The relative mRNA expression of the CDX1 (A) and CDX2 (B) of dysplasia and gastric 
cancer groups with the control group. Data are presented as means ± standard error.
C
D
X
1
/
β
-
a
c
t
i
n
C
D
X
2
/
β
-
a
c
t
i
n
  Control  Dysplasia   Cancer   Control  Dysplasia   Cancer
0.8
0.6
0.4
0.2
0.0
0.8
0.6
0.4
0.2
0.0
A B
0.53
0.59
0.44 0.45
0.24
P = 0.001 P = 0.100
P < 0.001 P < 0.001
0.34
Fig. 1. Correlation between CDX1 and CDX2 expression and grade of intestinal metaplasia. CDX1 in the antrum (A) and body (B), CDX2 in the antrum (C) and body (D). r, 
correlation coefficient.
C
D
X
1
/
β
-
a
c
t
i
n
C
D
X
1
/
β
-
a
c
t
i
n
Grade of intestinal metaplasia Grade of intestinal metaplasia
Antrum Body
r = 0.106, P = 0.081 r = 0.414, P < 0.001
  Absent  Mild  Moderate  Severe   Absent  Mild  Moderate  Severe
2.5
2.0
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
A B
C
D
X
2
/
β
-
a
c
t
i
n
C
D
X
2
/
β
-
a
c
t
i
n
Grade of intestinal metaplasia Grade of intestinal metaplasia
Antrum Body
r = 0.067, P = 0.273 r = 0.380, P < 0.001
  Absent  Mild  Moderate  Severe   Absent  Mild  Moderate  Severe
2.5
2.0
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
C DKang JM, et al.  •  CDX in Intestinal Metaplasia, Dysplasia, and Gastric Cancer
http://jkms.org   651 DOI: 10.3346/jkms.2011.26.5.647
study. Previous study showed that CDX2 expression tended to 
be positive in the antrum but was negative in the fundic muco-
sa in stomach lacking features of IM, whereas CDX2 tended to 
be positive in both antral and fundic mucosa in stomach with 
IM (10). Consequently, CDX2 expression may be evoked in the 
antrum before expression occurs in the fundic gland mucosa. 
Thus CDX2 expression in the body might reflect the status of gas-
tric IM more closely than that in the antrum although we did not 
measure CDX2 expression in the antrum. These findings sug-
gest that CDX1 and CDX2 may play a pivotal role in the devel-
opment of IM in the body but not the antrum, which is more 
strongly associated with development of GC than that in the 
antrum. However, the specific role of CDX1 and CDX2 in the 
determination of the IM subtype appears to be different. That 
is, IM in CDX1 transgenic mice show all of the cell types of IM 
including Paneth cells similar to the complete type of IM; on the 
other hand, IM in CDX2 transgenic mice have similar features 
with the incomplete type of IM (20). In the present study, CDX2 
expression was significantly higher in the incomplete type of 
corpus IM compared to the complete type, consistent with the 
findings of a previous study (21). However, the CDX1 expression 
was not different according to the subtype of IM. These results 
suggest that CDX2 plays a major role than CDX1 in the determi-
nation of the incomplete type of IM.
  Previous studies have suggested that CDX2 expression is as-
sociated not only with IM but also with early stage GC (11, 22, 
23). Recently, Mutoh et al. (24) reported that gastric polyps that 
develop from intestinal metaplastic mucosa of the stomach of 
CDX2 transgenic mice had intestinal type adenocarcinoma con-
taining p53 and APC gene mutations. On the other hand, some 
reports have suggested that CDX2 functions as a tumor suppres-
sor gene because of its role in the colon as a tumor suppressor 
gene (25). Furthermore, a decreased expression of CDX2 was 
associated with the progression of IM to dysplasia and cancer 
(17). However, induction of GC has also been observed in CDX2 
transgenic mice (24, 26). To date, the information on CDX2 ex-
pression in gastric epithelial dysplasia is limited and inconsis-
tent (13, 17, 27) and there is no study regarding CDX1 expres-
sion in gastric dysplasia. In the present study, aberrant expres-
sion of CDX1 and CDX2 was frequently observed in patients 
with GC and dysplasia although expression of CDX2 in dyspla-
sia did not reach statistical significance (P = 0.10). These results 
were further supported by additional findings that the grade of 
IM in the body was significantly higher in the dysplasia and can-
cer groups than in the control group. Taken together these find-
ings might suggest that CDX2 is involved in the development of 
cancer from dysplasia, which is different from CDX1. However, 
further molecular based studies are needed in the larger popu-
lation to elucidate the changes in the expression of CDX1 and 
CDX2 in the carcinogenesis from dysplasia to cancer. 
  Chronic H. pylori infection has been shown to induce CDX2 
expression in the human stomach prior to the development of 
IM (10, 18). In addition, in vitro H. pylori infection increased the 
expression of CDX2 in a gastric carcinoma cell line (AGS) (28). 
Furthermore, several studies have demonstrated that the ex-
pression of CDX2 was decreased after H. pylori eradication (29, 
30). However, there has been no study on the effects of H. pylori 
infection on CDX1 expression. In the present study, the expres-
sion of CDX2 was significantly higher in the H. pylori positive 
group than the H. pylori negative group consistent previous re-
port. Meanwhile, expression of CDX1 in H. pylori positive group 
tend to be higher than the H. pylori negative group without sta-
tistical significance (P = 0.191). From these results we can sug-
gest that CDX2 is closely related with H. pylori infection as well 
as IM grade but in case of CDX1 the trend is weak in terms of H. 
pylori infection. However, these might be originated from the 
small number of H. pylori negative group in the present study. 
Thus further study is needed to elucidate whether H. pylori-as-
sociated IM might be correlated with CDX1 in the larger popu-
lation without H. pylori.
  The present study had several advantage compared to the 
previous studies. First, it investigated CDX1 as well as CDX2 by 
quantitative analysis using real-time PCR. Second, in order to 
evaluate the effect of H. pylori infection on the expression of 
CDX1 and CDX2, four kinds of H. pylori tests (histology, CLOtest 
and culture from antrum and body, and serology to exclude the 
past infection) were used. Third, most of previous studies cov-
ered only gastric cancer patients but we evaluated cancer group 
as well as dysplasia group, and which age and sex were matched 
with control group. The number was 90 patients for each group. 
From this design we tried to provide a clue whether there is a 
difference of CDX1 and CDX2 in the role of gastric carcinogen-
esis. However, the study had limitation that RT-PCR for CDX1 
and CDX2 was only performed using specimens from the body 
but not from the antrum mainly from the availability of RNA. As 
Table 2. CDX1 and CDX2 expression by real­time PCR according to H. pylori positivity, 
the presence and subtype of intestinal metaplasia
Variables CDX1 P value CDX2 P values
H. pylori positivity 
   Negative (n = 45)
   Positive (n = 225)
 
0.32 ± 0.07
0.42 ± 0.03
0.191  
0.34 ± 0.07
0.49 ± 0.03
0.045
Presence of IM (Antrum)
   Absent (n = 32)
   Present (n = 238)
 
0.36 ± 0.08
0.41 ± 0.03
0.587  
0.48 ± 0.08
0.46 ± 0.03
0.836
Subtype of IM (Antrum)
   Complete (n = 21)
   Incomplete(n = 147)
 
0.37 ± 0.11
0.41 ± 0.04
0.774  
0.35 ± 0.10
0.49 ± 0.04
0.159
Presence of IM (Body)
   Negative (n = 100)
   Positive (n = 170)
 
0.20 ± 0.04
0.53 ± 0.03
< 0.001  
0.26 ± 0.04
0.58 ± 0.03
< 0.001
Subtype of IM (Body)
   Complete (n = 34)
   Incomplete (n = 99)
 
0.42 ± 0.08
0.54 ± 0.04
0.191  
0.46 ± 0.08
0.64 ± 0.04
0.045
Data are presented as means ± standard error. IM, intestinal metaplasia. Bold letters 
indicate statistical significance.Kang JM, et al.  •  CDX in Intestinal Metaplasia, Dysplasia, and Gastric Cancer
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the analysis of CDX1 and CDX2 was not performed in the an-
trum the levels of expression of CDX1 and CDX2 regarding to 
the presence of IM or subtype of IM were not clearly shown in 
the antrum as in the body. 
  In conclusion, aberrant expression of CDX1 and CDX2 is cor-
related with H. pylori infection and grade of IM in the body. It is 
suggested that CDX1 and CDX2 play a role in the carcinogene-
sis of the stomach.
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addition, CDX1 and CDX2 in cancer group was significantly higher than control group. Aberrant expression of CDX1 and CDX2 
correlated with H. pylori infection and grade of IM in the body. Furthermore, the results suggest that CDX1 and CDX2 play a role 
in the progression to GC and dysplasia.
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